The Research Progress of Direct KRAS G12C Mutation Inhibitors

被引：13

作者：

Yang, Ai ^{[1
]}

Li, Min ^{[1
]}

Fang, Mingzhi ^{[1
]}

机构：

[1] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Dept Oncol, Nanjing, Peoples R China

来源：

PATHOLOGY & ONCOLOGY RESEARCH | 2021年 / 27卷

关键词：

KRAS mutation; targeted drugs; oncogene; inhibitor; oncology; SMALL-MOLECULE INHIBITORS; AMG; 510; KRAS(G12C) INHIBITOR; AFFINITY; CANCER; GTP;

D O I：

10.3389/pore.2021.631095

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevant drugs under study and challenges that need to be considered in future research.

引用

页数：8

共 50 条

[1] The Research Progress of Direct KRAS G12C Mutation Inhibitors (vol 27, 631095, 2021)
Yang, Ai
Li, Min
Fang, Mingzhi
PATHOLOGY & ONCOLOGY RESEARCH, 2022, 27
[2] KRAS G12C mutation is not undruggable anymore
Rodrigues, Manuel
BULLETIN DU CANCER, 2020, 107 (02) : 145 - 145
[3] Targeting KRAS G12C with Covalent Inhibitors
Ostrem, Jonathan M. L.
Shokat, Kevan M.
ANNUAL REVIEW OF CANCER BIOLOGY, 2022, 6 : 49 - 64
[4] Mechanisms of Resistance to KRAS G12C Inhibitors
Ambrogio, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S96 - S96
[5] Clinical Data for KRAS G12C Inhibitors
Kim, H. R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S95 - S96
[6] The promise and peril of KRAS G12C inhibitors
Moore, Amanda R.
Malek, Shiva
CANCER CELL, 2021, 39 (08) : 1059 - 1061
[7] Targeting KRAS G12C mutation in lung adenocarcinoma
Rohatgi, Anjali
Govindan, Ramaswamy
LUNG CANCER, 2022, 165 : 28 - 33
[8] Development of inhibitors of the activated form of KRAS G12C
Pollock, R.
Stewart, M.
Perl, N.
Lee, S. J.
Xue, L.
Zhou, M.
Simon, J.
Luly, K.
Grigoriu, S.
Yuzhakov, A.
Silver, A.
Lowe, J.
Mann, A.
Verdine, G.
Rigby, A.
Mulvihill, M.
May, E.
Kohlmann, A.
Townson, S.
Jin, M.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E52 - E52
[9] Covalent Guanosine Mimetic Inhibitors of G12C KRAS
Xiong, Yuan
Lu, Jia
Hunter, John
Li, Lianbo
Scott, David
Choi, Hwan Geun
Lim, Sang Min
Manandhar, Anuj
Gondi, Sudershan
Sim, Taebo
Westover, Kenneth D.
Gray, Nathanael S.
ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 61 - 66
[10] Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance
Jiang, Zhiyan
Li, Yan
Zhou, Xin
Wen, Jie
Zheng, Pengwu
Zhu, Wufu
BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 100

← 1 2 3 4 5 →